Brain cancer breakthrough provides hope for new treatments
A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.
May 10, 2021
0
10
A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.
May 10, 2021
0
10
The human immune system doesn't just protect our health, it reflects it. Each encounter with a potential disease-causing agent causes the body to produce specific immune agents—proteins known as antibodies and T-cell receptors—tailor-made ...
May 4, 2021
0
4
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional ...
Apr 11, 2021
0
4
Children and young adults who receive CAR T-cell therapy for the most common childhood cancer, acute lymphoblastic leukemia, suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired ...
Apr 1, 2021
0
6
Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, the agency announced Saturday.
Mar 31, 2021
0
3
Researchers led by Professor Carolyn King of the University of Basel have developed a method to study the specialization of T cells in the context of infections. In the journal eLife, they report the different directions ...
Mar 10, 2021
0
12
Insight into cancer cells' own first aid could help the development of a new type of treatment. Johanna Olweus and her team at the UiO (University of Oslo) and the OUS (Oslo University Hospital) are important contributors ...
Jan 27, 2021
0
5
Activating an immune signaling pathway best known for fighting viral and bacterial infections can boost the ability of genetically engineered T cells to eradicate breast cancer in mice, according to a new study by researchers ...
Dec 31, 2020
0
21
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients ...
Dec 7, 2020
0
2
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187